Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27682718 | 0.91 | KMT2A (0.62) | CYP1A2ALDH1A1MAPTGAAHTT | |
| SCHEMBL2515018 | 0.87 | EPHX2 (0.58) | CYP1A2ALDH1A1MAPTGAAHTT | |
| SCHEMBL4351772 | 0.85 | EPHX2 (0.63) | CYP1A2ALDH1A1MAPTGAAHTT | |
| SCHEMBL2094767 | 0.85 | NPC1 (0.63) | ALDH1A1MAPTGAAHTTHPGD | |
| SCHEMBL23240195 | 0.85 | ALDH1A1 (0.48) | CYP1A2ALDH1A1MAPTGAAHTT | |
| SCHEMBL29716280 | 0.85 | ALDH1A1 (0.48) | CYP1A2ALDH1A1MAPTGAAHTT | |
| SCHEMBL2095975 | 0.84 | ALDH1A1 (0.60) | ALDH1A1MAPTGAAHTTHPGD | |
| SCHEMBL8048626 | 0.84 | CYP1A2 (0.76) | CYP1A2ALDH1A1MAPTGAAHTT | |
| SCHEMBL29739464 | 0.84 | CYP1A2 (0.62) | CYP1A2ALDH1A1MAPTGAAHTT | |
| SCHEMBL2094765 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPTGAAHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662206-A1 | GSPT1 DEGRADER COMPOUNDS | Captor Therapeutics S.A. (PL) | 2025-12-17 | — | — | EP | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| WO-2024165577-A1 | GSPT1 DEGRADER COMPOUNDS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024167423-A1 | GSPT1 DEGRADER COMPOUNDS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-08-15 | — | — | WO | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4323350-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-1993361-A | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORP (US) | 2007-07-04 | — | — | CN | disclosed |
| WO-2006043090-A1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-04-27 | — | — | WO | disclosed |
| US-20050250816-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| US-20050154230-A1 | Urea derivatives | BAYER HEALTHCARE AG (DE) | 2005-07-14 | — | — | US | disclosed |
| US-20040254373-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PFIZER INC | 2004-12-16 | — | — | US | disclosed |
| US-20040249150-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PFIZER INC | 2004-12-09 | — | — | US | disclosed |
| EP-1461311-A2 | UREA DERIVATIVES AS VR1-ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| US-20030236287-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003093250-A2 | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003055848-A2 | UREA DERIVATIVES AS VR1- ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254373-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | CHRNA1, CHRNB1, CHRM1 | CYP1A2 1827/4885ALDH1A1 2007/4885MAPT 1550/4885 |
| US-20030236287-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | CHRNA1, CHRNB1, CHRM1 | CYP1A2 1827/4885ALDH1A1 2007/4885MAPT 1550/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CYP1A2 146/4885ALDH1A1 1142/4885MAPT 4795/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | CYP1A2 146/4885ALDH1A1 1142/4885MAPT 4795/4885 |
| US-20050154230-A1 | Urea derivatives | SLC14A1, UBA1, VAT1 | CYP1A2 3223/4885ALDH1A1 218/4885MAPT 2294/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | CYP1A2 1677/4885ALDH1A1 4150/4885MAPT 4671/4885 |
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | CYP1A2 4774/4885ALDH1A1 4088/4885MAPT 3269/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CYP1A2 146/4885ALDH1A1 1142/4885MAPT 4795/4885 |
| US-20040249150-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | CHRNA1, CHRNB1, CHRM1 | CYP1A2 1827/4885ALDH1A1 2007/4885MAPT 1550/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | CYP1A2 4692/4885ALDH1A1 4276/4885MAPT 3196/4885 |
| US-20050250816-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | CHRNA7, CHRNA1, CHRNA5 | CYP1A2 1913/4885ALDH1A1 2742/4885MAPT 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.